GlucaGen® HypoKit® Overview
GlucaGen® HypoKit® is an emergency treatment designed for individuals experiencing severe hypoglycemia, particularly those with diabetes. It contains glucagon, a hormone that stimulates the liver to release stored glucose into the bloodstream, thereby raising blood sugar levels. The kit is essential for people who may become incapacitated due to low blood sugar and cannot consume sugar orally.
Discontinuation of GlucaGen® HypoKit®
Novo Nordisk has announced that it will permanently discontinue the manufacture and distribution of GlucaGen® HypoKit® in the U.S. effective July 1, 2024. This decision stems from a global shortage of pre-filled syringes sourced from an external vendor. In light of this discontinuation, Novo Nordisk has prioritized supplying GlucaGen® in markets where no alternative treatments are available, as there are other hypoglycemia rescue medications accessible in the U.S.
https://omcpharmacy.org/product/buy-glucagen-hypokit-hypoglycemia-treatment-emergency-injector/
Usage Instructions
The GlucaGen® HypoKit® is intended for use when someone is experiencing severe hypoglycemia and cannot treat themselves. The kit includes a vial of dry glucagon powder and a syringe filled with sterile water for reconstitution. Users must follow specific steps to prepare and administer the injection:
- Preparation: Mix the glucagon powder with sterile water using the provided syringe.
- Injection: Administer the mixed solution via subcutaneous injection into areas such as the upper arm, thigh, or buttocks.
- Post-Injection Care: After administering glucagon, turn the person on their side to prevent choking if they regain consciousness.
Alternatives and Recommendations
Given that GlucaGen® HypoKit® will no longer be available after July 1, 2024, it is crucial for patients to consult healthcare providers about alternative treatment options to ensure continuity of care during emergencies related to hypoglycemia.
Safety Information
Certain individuals should not use GlucaGen®, including those with specific tumors (pheochromocytoma or insulinoma), allergies to glucagon or its components, or conditions that may lead to inadequate hepatic glycogen stores (e.g., prolonged starvation). Side effects can include nausea, vomiting, headache, dizziness, and potential allergic reactions.
In summary, while GlucaGen® HypoKit® has been an essential tool for managing severe hypoglycemia in diabetic patients, its upcoming discontinuation necessitates proactive discussions with healthcare providers regarding alternative treatments.
https://omcpharmacy.org/